Delving into the Latest Updates on Federal Research Institute of Pediatric Hematology, Oncology and Immunology with Synapse

Overview

Tags

Immune System Diseases

Hemic and Lymphatic Diseases

Neoplasms

Autologous CAR-T

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	1
Immune System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Autologous CAR-T	1

Top 5 Target	Count

CD19 x CD22	1

Prospective Pilot Study of the Clinical Efficacy and Safety of the Method for Preventing a Graft-versus-host Disease Through the Agency of Using the Combination of Post-transplantation Cyclophosphamide With Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis After Hematopoietic Stem Cell Transplantation From an Unrelated or Haploidentic Donor

GVHD prevention using a combination of post-transplantation cyclophosphamide in combination with abatacept, vedolizumab and and Baricitinib in children and young adults with hematoloblastosis after myeloablative conditioning regimen with treosulfan/TBI, cyclophosphamide/etoposide, fludarabine after HSCT from matched unrelated and haploidentical donors

Start Date01 Dec 2023

Sponsor / Collaborator

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

NCT06198842 / RecruitingPhase 2IIT

Clinical Open-label Phase 2 Study of Low Dose Treosulfan Based Conditioning Regimen Efficacy in Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide for Children Nijmegen Breakage Syndrome

The aim of the current study is to evaluate the safety and efficacy of low dose treosulfan based conditioning regimen in HSCT with post-transplant cyclophosphamide in Nijmegen breakage syndrome

Start Date22 Nov 2023

Sponsor / Collaborator

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

100 Clinical Results associated with Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Login to view more data

0 Patents (Medical) associated with Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Login to view more data

100 Deals associated with Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Login to view more data

100 Translational Medicine associated with Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Login to view more data